Dr. Reddy's Laboratories Limited

RDY· NYSE· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$12.06+1.81%

2026-08-03

Financials

Valuation Metrics

Dr. Reddy's Laboratories Limited's Market Cap is $10.07B. Ranked #944 of 3,112 in US market (top 30%), #642 of 1,667 on NYSE (top 39%), #46 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$10.07B	US#944/3,112 Sec#46/269
Revenue	$3.82B	US#1,071/3,112 Sec#32/269
Net Income	$486M	US#827/3,112 Sec#31/269
Total Assets	$6.02B	US#1,309/3,112 Sec#35/269
Net Assets	$3.92B	US#831/3,112 Sec#33/269
Value
P/E	20.73x	US#1,065/3,112 Sec#38/269
P/B	2.57x	US#1,495/3,112 Sec#71/269
P/S	2.64x	US#1,580/3,112 Sec#44/269
EV/EBITDA	12.24x	US#1,103/3,112 Sec#35/269
FCF Yield	2.73%	US#1,810/3,112 Sec#61/269
Profitability
ROE	12.40%	US#1,083/3,112 Sec#51/269
ROA	8.07%	US#609/3,112 Sec#41/269
Op. Margin	14.74%	US#1,248/3,112 Sec#51/269
Revenue Growth	-10.26%	US#2,664/3,112 Sec#147/269
Earnings Growth	-85.98%	US#2,016/3,112 Sec#62/269
Financial Health
Debt Ratio	52.75%	US#605/3,112 Sec#141/269
Total Debt	$803M	US#1,586/3,112 Sec#48/269
FCF	$275M	US#1,186/3,112 Sec#38/269
Cash	$160M	US#1,901/3,112 Sec#141/269
Current Ratio	1.80x	US#1,384/3,112 Sec#235/269
Net Debt/EBITDA	0.74x	US#921/3,112 Sec#46/269
Dividend
Div. Yield	0.75%	US#1,401/3,112 Sec#20/269
Div. Growth	5.17%	US#801/3,112 Sec#10/269
Performance
1Y Return	-13.45%	US#2,418/3,112 Sec#215/269
1M Return	-16.10%	US#2,848/3,112 Sec#212/269
From 52W High	-23.01%	US#1,854/3,112 Sec#126/269
1Y MDD	-26.01%	US#1,101/3,112 Sec#62/269
Trading
Volume	3,160,553 shares	US#599/3,112 Sec#50/269
Trading Value	$38M	US#1,557/3,112 Sec#101/269